/stocks — the workspaceLOADING
All NVSSEC filings, by type → · Earnings date & implied move · Search inside filings
NOVARTIS AG (NVS) is a pharmaceutical preparations company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind NVS’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has NVS been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
A plain-English read on NVS plus an auto-SWOT — built from NVS's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate NVS using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from NVS's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentNVS files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| Alan ArmstrongU.S. Senator | BUY | $1,001 - $15,000 | filed 2026-07-21 |
| Alan ArmstrongU.S. Senator | BUY | $15,001 - $50,000 | filed 2026-07-21 |
Total return including reinvested dividends, from NVS’s adjusted closing prices. Past return is not a forecast and not investment advice.